Furthermore, Karanam et al. [61] showed that hsa-miR-551b-3p promoted tumor growth, invasion, and metastasis by targeting GLIPR2 in high-risk head and neck cancer, and Chang et al. [62] reported that hsa-miR-551b-3p targeted cyclin D1 and inhibited tumor growth in cholangiocarcinoma. Here, CCND1 is linked to cholangiocarcinoma.